

INFORMATION DISCLOSURE STATEMENT

Applicants wish to have the Examiner make of record in this application, the references previously disclosed in the related co-assigned U.S. Serial No. 806,112, filed December 12, 1991, now U.S. Patent No. 5,401,638. In accordance with their duty under 37 C.F.R. §1.56, applicants would like to direct the Examiner's attention to the following:

1. U.S. Patent 4,753,894.
2. U.S. Patent 4,803,169.
3. Johnson et al., U.S. Patent No. 4,855,241.
4. U.S. Patent 4,938,948.
5. U.S. Patent 5,169,774.
6. EP-A-O 206065.
7. EP-A-O 214520.
8. WO 87/06692.
9. Akiyama et al., Science, 232:1644-1646 (1986).
10. Bargmann et al., Cell, 45:649-657 (1986).
11. Bargmann et al., Nature, 319:226-230 (1986).
12. Basu et al., Mol. Cell. Biol., 9:671-677 (1989).
13. Berger et al., Cancer Res., 48:1238-1243 (1988).
14. Carney et al., AACC Abstract (1988).
15. Coussens et al., Science, 230:1132-1139 (1985).
16. Downing et al., Mol. Cell. Biol., 9:2890-2896 (1989).
17. Drebin et al., Nature, 312:545-548 (1984).
18. Drebin et al., Cell, 41:695-706 (1985).
19. Drebin et al., Oncogene, 2:273-277 (1988).
20. Drebin et al., Oncogene, 2:387-394 (1988).
21. Gullick et al., Int. J. Cancer, 40:246-254 (1987).
22. Hung et al., Proc. Natl. Acad. Sci. USA, 83:261-264 (1986).
23. Kraus et al., The EMBO J., 6:605-610 (1987).
24. McKenzie et al., Oncogene, 4:543-548 (1989).
25. McKenzie et al., Abstract presented at 4th Annual Oncogene Meeting, Frederick, Maryland (1988).

B

Applicants: Walter P. Carney et al.  
Serial No.: 08/488,180  
Filed: June 7, 1995  
Page 15

26. Schecter et al., Science, 229:976-978 (1985).
27. Semba et al., Proc. Natl. Acad. Sci. USA, 82:6497-6501 (1985).
28. Slamon et al., Science, 235:177-182 (1987).
29. Studencki et al., DNA, 3:7-15 (1984).
30. Tandon et al., J. Clin. Oncol., 7:1120-1128 (1989).
31. Trimpe et al., Abstract presented at Cold Spring Harbor Laboratory Meeting (1988).
32. Van de Vijer et al., Mol. Cell. Biol., 7:2019-2023 (1987).
33. Varley et al., Oncogene, 1:423-430 (1987).
34. Venter et al., The Lancet, ii:69-72 (1987).
35. Wong et al., Oncogene, 2:67-72 (1987).
36. Yamamoto et al., Nature, 319:230-234 (1986).

Copies of the disclosed references were submitted in the parent application and therefore, pursuant to 37 C.F.R. §1.98, are not required to be submitted in the subject application. Each of the references listed above are again listed on the accompanying PTO Form 1449 (**Exhibit B**). Accordingly, applicants maintain that none of the above-listed references teach or suggest the inventions claimed in the subject application.


If a telephone interview would be of assistance in advancing prosecution of the subject application, applicants' undersigned attorney invites the Examiner to telephone him at the number provided below.

B


Applicants: Walter P. Carney et al.  
Serial No.: 08/488,180  
Filed: June 7, 1995  
Page 16

No fee is deemed necessary in connection with the filing of this Amendment other than the \$950.00 extension of time fee, the \$66.00 claims fee and the \$240.00 Information Disclosure Statement fee. However, if any additional fee is required, authorization is given to charge the amount of any such fee to Deposit Account No. 03-3125.

Respectfully submitted,



John P. White  
Registration No. 28,678  
Attorney for Applicants  
Cooper & Dunham LLP  
1185 Avenue of the Americas  
New York, New York 10036  
(212) 278-0400

I hereby certify that this correspondence is being deposited this date with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner of Patents and Trademarks, Washington, D.C. 20231.	
 John P. White Reg. No. 28,678	10/2/97 Date

B